Fig. 3From: The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysisThe Risk of Bias version 2 (Rob v2) graph for assessment of randomized controlled trialsBack to article page